Relmada Therapeutics Statistics
Want to see RLMD full AI Analyst Report?
Relmada Therapeutics (RLMD) Stock Statistics & Valuation Metrics
Total Valuation
Relmada Therapeutics has a market cap or net worth of $449.19M. The enterprise value is $221.77M.
- Market Cap
- $449.19M
- Enterprise Value
- $221.77M
Share Statistics
Relmada Therapeutics has 106,694,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 106,694,850
- Owned by Insiders
- 3.19%
- Owned by Institutions
- 44.13%
Financial Efficiency
Relmada Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -67.49%.
- Return on Equity (ROE)
- -0.66
- Return on Assets (ROA)
- -0.61
- Return on Invested Capital (ROIC)
- -67.49%
- Return on Capital Employed (ROCE)
- -0.67
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.38M
- Employee Count
- 17
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Relmada Therapeutics is -5.69. Relmada Therapeutics’s PEG ratio is -0.05.
- PE Ratio
- -5.69
- PS Ratio
- 0.00
- PB Ratio
- 2.44
- Price to FCF
- -8.66
- Price to Operating Cash Flow
- -9.13
- PEG Ratio
- -0.05
Income Statement
In the last 12 months, Relmada Therapeutics had revenue of 0 and earned -57.39M in profits. Earnings per share was -1.45.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -59.10M
- Pretax Income
- -57.39M
- Net Income
- -57.39M
- EBITDA
- -57.39M
- Earnings Per Share (EPS)
- -1.45
Cash Flow
In the last 12 months, operating cash flow was -51.86M and capital expenditures 0, giving a free cash flow of -51.86M billion.
- Operating Cash Flow
- -51.86M
- Free Cash Flow
- -51.86M
- Free Cash Flow per Share
- -0.46
Dividends & Yields
Relmada Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.54%
- Earnings Yield
- -13.88%
Stock Price Statistics
- Beta
- 1.30
- 52-Week Price Change
- 8.51%
- 50-Day Moving Average
- 3.77
- 200-Day Moving Average
- 5.40
- Relative Strength Index (RSI)
- 59.30
- Average Volume (3m)
- 1.36M
Important Dates
Relmada Therapeutics upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Relmada Therapeutics as a current ratio of 14.62, with Debt / Equity ratio of 0.00%
- Current Ratio
- 14.62
- Quick Ratio
- 14.62
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.06
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Relmada Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Relmada Therapeutics EV to EBITDA ratio is -6.83, with an EV/FCF ratio of -8.55.
- EV to Sales
- 0.00
- EV to EBITDA
- -6.83
- EV to Free Cash Flow
- -8.55
- EV to Operating Cash Flow
- -8.55
Balance Sheet
Relmada Therapeutics has $202.12M in cash and marketable securities with $0.00 in debt, giving a net cash position of $202.12M billion.
- Cash & Marketable Securities
- $202.12M
- Total Debt
- $0.00
- Net Cash
- $202.12M
- Net Cash Per Share
- $1.89
- Tangible Book Value Per Share
- $1.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Relmada Therapeutics is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $12.00
- Price Target Upside
- 185.04% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 58.31%
Scores
- Smart Score
- 7
- AI Score
- 58

